【1 月 20 日,招银国际报告称药明生物表现出色】药明生物去年新增 151 个项目创新高,赋能 7 个分子研究服务全球项目,近期有权收取约 1.4 亿美元款项。海外业务稳步推进,爱尔兰生产设施有望今年收支平衡。管理层重申去年指引,预期收入及经调整盈利均增长 5%至 10%,对今年收入增长加速有信心。去年完成工艺性能确认(PPQ)项目 77 个,按年增长 26%,预计今年增长 31%至 101 个...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.